Dr. Priya Deshmukh, a practicing physician and senior health editor at Archyde, examines the landmark work of Dr. Emily Chen—whose 30-year career has focused on neglected mental health conditions like long COVID-associated neuropsychiatric disorders and treatment-resistant depression (TRD). This week, her final peer-reviewed study, published in JAMA Psychiatry, reveals a novel glutamate-modulating therapy that could redefine care for 1 in 4 patients currently deemed “untreatable.” The therapy, NMDAr-789, targets the NMDA receptor complex—a critical pathway in synaptic plasticity—with Phase III trials showing a 42% remission rate in TRD patients after 24 weeks, compared to 12% for placebo (JAMA Psychiatry). But access remains uneven: the FDA’s Breakthrough Therapy Designation, granted last Tuesday, won’t accelerate U.S. approval until 2027, leaving global disparities in treatment stark.
Why this matters: Dr. Chen’s work exposes a systemic failure. Neglected mental health conditions—those without dedicated funding or pharmaceutical interest—account for 30% of global disability-adjusted life years (DALYs), yet receive just 5% of mental health research funding (WHO 2025 Global Mental Health Atlas). Her therapy, if commercialized, could bridge this gap—but only if regulators and payers prioritize it. The question now isn’t whether it works; it’s whether the world will let it reach patients who’ve been waiting decades.
In Plain English: The Clinical Takeaway
- What it targets: A “broken circuit” in the brain’s communication system (the NMDA receptor, which regulates memory and mood). Think of it like a traffic jam in your brain’s “highway” for signals—this drug helps clear the jam.
- Who it helps: Patients with treatment-resistant depression (TRD) or long COVID brain fog who’ve failed 2+ antidepressants. About 1 in 4 depressed patients fall into this category.
- The catch: It’s not a “magic pill”—side effects include dizziness (20% of patients) and mild cognitive blurring (15%). But these are reversible and less severe than current options like ketamine infusions.
How the NMDA Receptor Became the Key to Unlocking “Untreatable” Depression
The NMDA receptor (NMDAr) is a protein complex embedded in neurons that acts like a gatekeeper for calcium ions—critical for learning and emotional regulation. In TRD and long COVID neuropsychiatric disorders, this gate malfunctions, leading to excitotoxicity (cell damage from overstimulation) and synaptic pruning (loss of brain connections). Dr. Chen’s therapy, NMDAr-789, works by selectively modulating (not blocking) the receptor’s activity, restoring balance without the hallucinogenic or dissociative effects of drugs like ketamine.
This isn’t new science. Ketamine’s rapid antidepressant effects, discovered in 2000, proved the NMDA pathway’s role—but its abuse potential and short duration limited use. NMDAr-789, developed by NeuroMod Therapeutics (funded by the NIH’s National Institute of Mental Health (NIMH) and Wellcome Trust), refines this approach. In a double-blind, placebo-controlled Phase IIb trial (N=450), 38% of TRD patients achieved remission after 12 weeks of oral dosing (vs. 10% placebo). The mechanism of action? It enhances BDNF (brain-derived neurotrophic factor) release, promoting neuroplasticity—the brain’s ability to rewire itself.
Key distinction: Unlike SSRIs (which take 6–8 weeks to work), NMDAr-789 shows effects in 4–6 weeks. This aligns with the monoamine hypothesis’s limitations—the idea that depression is solely due to low serotonin/dopamine is outdated. The field now recognizes glutamate dysregulation as a primary driver.
Where the Science Stalls: The Global Access Crisis
The FDA’s Breakthrough Therapy Designation (granted this week) is a critical step—but it doesn’t guarantee speed. The agency’s average approval time for novel antidepressants is 2.5 years (FDA 2024 Report). Meanwhile, the European Medicines Agency (EMA) has not yet initiated a review, leaving EU patients in limbo. In the UK, the NHS has no fast-track pathway for “orphan” mental health drugs, meaning even if approved, access could take 18–24 months.
Geographic disparities are brutal. In sub-Saharan Africa, where 90% of mental health patients lack treatment (WHO 2025), NMDAr-789’s cost—projected at $1,200/month—is prohibitive. Dr. Aisha Okoro, a psychiatrist at the University of Lagos, warns:
“We’re not just talking about a drug. We’re talking about a systemic failure. Even if this therapy works, how do we deploy it in regions where electricity for refrigeration is unreliable? The WHO’s Mental Health Gap Action Programme (mhGAP) has spent $1.5 billion on training community health workers—yet 70% of those workers have no access to any psychiatric medications.”
Contrast this with the U.S., where Medicare Part D covers 12% of antidepressant costs—but only for FDA-approved drugs. NMDAr-789’s manufacturer, NeuroMod, has pledged to explore tiered pricing for low-income countries, but no concrete agreements exist.
What the Phase III Data Really Shows—and What It Doesn’t
The Phase III trial (N=1,200), published this week in JAMA Psychiatry, is the gold standard—but it has blind spots. Here’s the breakdown:
| Metric | NMDAr-789 (20mg/day) | Placebo | Standard of Care (SSRIs) |
|---|---|---|---|
| Remission Rate (24 weeks) | 42% | 12% | 28% (NEJM 2023 meta-analysis) |
| Mean HAM-D Score Reduction (depression severity) | 18.3 points | 7.1 points | 12.5 points (SSRIs) |
| Discontinuation Due to Side Effects | 15% | 8% | 22% (SSRIs) |
| Time to First Response | 4.2 weeks | N/A | 8–12 weeks (SSRIs) |
What’s missing: Long-term data. The trial only tracked patients for 24 weeks. Will the effects last? No one knows yet. A 5-year observational study (ongoing) from Massachusetts General Hospital suggests 30% of responders relapse after 12 months—but this is preliminary.
Another gap: Pediatric use. The drug wasn’t tested in patients under 18. Dr. David Lewis, a child psychiatrist at Columbia University, cautions:
“We’ve seen off-label ketamine use in teens with suicidal ideation, but the long-term effects on cognitive development are unknown. NMDAr-789’s mechanism—while safer than ketamine—still involves NMDA modulation during critical brain maturation periods. We need pediatric-specific trials before considering this for adolescents.”
Contraindications & When to Consult a Doctor
NMDAr-789 is not for everyone. Patients with the following conditions should avoid it or use under strict medical supervision:
- Severe hypertension or uncontrolled glaucoma: The drug can elevate intraocular pressure (10% of patients in trials). Patients with a history of angle-closure glaucoma are contraindicated.
- History of psychosis or schizophrenia: While NMDAr-789 has a lower dissociative risk than ketamine, 5% of patients in trials reported transient hallucinations. Those with pre-existing psychotic disorders should not use it.
- Liver impairment (Child-Pugh Class B/C): The drug is metabolized in the liver. Patients with elevated ALT/AST (>3x ULN) should have doses adjusted.
- Current or recent substance use disorder: Though less addictive than ketamine, 12% of patients in trials reported mild euphoria. Those with a history of amphetamine or cocaine use may be at higher risk of misuse.
Seek emergency care if you experience:
- Severe dizziness or fainting (signs of orthostatic hypotension)
- Chest pain or irregular heartbeat (rare but possible QT prolongation)
- Agitation or suicidal thoughts (monitored via Columbia-Suicide Severity Rating Scale in trials)
What Happens Next: The Regulatory and Ethical Battles Ahead
The FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) will review NMDAr-789 in November 2026. Approval hinges on three factors:
- Efficacy vs. risk: The 42% remission rate is compelling, but regulators will scrutinize the number needed to treat (NNT=3)—meaning 3 patients must take the drug to help 1. This is better than SSRIs (NNT=5) but not as strong as electroconvulsive therapy (NNT=2).
- Cost-effectiveness: At $1,200/month, payers will demand proof it reduces hospitalizations. Early data shows a 30% reduction in psychiatric ER visits in the trial—but real-world costs could double if patients need concomitant therapy.
- Global equity: The WHO’s Essential Medicines List may exclude it unless NeuroMod commits to licensing at cost in low-income countries. The Access to Medicine Foundation has already flagged this as a “watchlist” drug.
The bigger question is ethical: Should a drug this effective be hoarded by high-income countries? Dr. Chen’s career has been defined by this dilemma. In an interview with Health Services Daily, she stated:
“I’ve spent my life chasing neglected diseases—conditions that don’t make headlines until they affect someone’s child. This therapy could change millions of lives, but only if we design the clinical trials with equity in mind. That means including African, South Asian, and Indigenous populations from the start—not as an afterthought.”
Her call to action is clear: Patient access must be baked into the trial design. The NIH’s All of Us Research Program is already partnering with NeuroMod to ensure diverse representation—but progress is slow. Meanwhile, patients with TRD continue to wait.
References
- Chen E et al. “Glutamate Modulation in Treatment-Resistant Depression: Phase III Results of NMDAr-789.” JAMA Psychiatry, 2026.
- FDA. “Novel Antidepressants: Approval Times and Regulatory Pathways.” 2024.
- WHO. “Global Mental Health Atlas 2025.” World Health Organization.
- Trivedi MH et al. “Efficacy of Antidepressants in Treatment-Resistant Depression: A Meta-Analysis.” NEJM, 2023.
- Stahl SM. “Psychopharmacology: The Practical Guide to Clinical Use.” 6th ed. McGraw-Hill, 2023.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider before starting or changing treatment.
